On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs that won marketing approval in the U.S. during the last two decades took 14% less time to undergo clinical trials and obtain regulatory approval compared to other drugs that came to market during the same period.